September 06, 2025

Get In Touch

Statins Linked To Initial Increase In Polyneuropathy Risk In Diabetes: Study

Denmark: Statin therapy does not mitigate or increase the risk of diabetic polyneuropathy (DPN) in type 2 diabetes (T2D) patients, according to a recent study in the journal Diabetes Care. However, during the first year, there was a slightly increased DPN risk among new users but it receded after >2 years of the study.
Owing to lipid-lowering and anti-inflammatory effects statins may reduce diabetic polyneuropathy (DPN) risk but also, their use has been associated with neurotoxicity. Frederik P. Kristensen, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark, and colleagues examined whether statin therapy affects the risk of DPN.
The researchers identified all Danish patients with incident type 2 diabetes during 2002–2016. The initiation of statin in new users was done between 180 days before and 180 days after their first diabetes record. Prevalent users had initiated statins before that period. Patients were followed for incident diabetic polyneuropathy (DPN) using validated hospital diagnosis codes, starting 180 days after their first diabetes record
The study cohort consiaited of 59,255 (23%) new users, 75,528 (29%) prevalent users, and 124,842 (48%) nonusers; median follow-up time was 6.2 years.
Key findings of the study include:
The incidence rate of DPN events per 1,000 person-years was similar in new users (4.0), prevalent users (3.8) and nonusers (3.8).
The aHR for DPN was 1.05 in new users and 0.97 in prevalent users compared with statin nonusers.
New users had a slightly increased DPN risk during the first year (1.31), which vanished after >2 years of follow-up.
Findings were similar in on-treatment and propensity score-matched analyses and with additional adjustment for pretreatment blood lipid levels.
"Statin therapy is unlikely to increase or mitigate diabetic polyneuropathy (DPN) risk in patients with type 2 diabetes, although a small acute risk of harm cannot be excluded," concluded the authors.
"Statin Therapy and Risk of Polyneuropathy in Type 2 Diabetes: A Danish Cohort Study," is published in the journal Diabetes Care.
DOI: https://care.diabetesjournals.org/content/early/2020/09/29/dc20-1004

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!